Xtandi 80 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB25FWQT4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,170
Award facts
- Contract value 100% obligated
- $4,169.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 by the Defense Logistics Agency (DLA) on July 22, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This firm fixed-price delivery order, with an ultimate completion date of July 23, 2025, represents a discrete purchase under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the DLA under the SPE2DB program. The SPE2DB IDC, valued at $499,999,999 and valid through November 2026, authorizes the DLA to issue delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare facilities worldwide. No set-aside designation was applied to this award.
Xtandi is an oncology medication used in the treatment of certain prostate cancers, reflecting DMS Pharmaceutical Group's established role as a critical supplier of specialized pharmaceutical products to federal military health systems. The company's contract portfolio demonstrates consistent success in competing for federal pharmaceutical procurement without specific small business set-aside designations, leveraging its woman-owned small business status and established vendor relationships with the DLA. The delivery location for this order is the company's headquarters facility in Park Ridge, Illinois.
Quick answers
Who was awarded contract SPE2DB25FWQT4?
SPE2DB25FWQT4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 22, 2025.
How much is contract SPE2DB25FWQT4 worth?
The government has obligated $4,170 on SPE2DB25FWQT4.
Is contract SPE2DB25FWQT4 an order under another contract?
Yes. SPE2DB25FWQT4 is a delivery order under SPE2DB24D9218, an indefinite delivery contract.
Was contract SPE2DB25FWQT4 competed?
The extent of competition for SPE2DB25FWQT4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award